AGIOS PHARMACEUTICALS, INC. (AGIO) Q3 2025 10-Q Quarterly Report
AGIOS PHARMACEUTICALS, INC. (AGIO) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AGIOS PHARMACEUTICALS, INC. Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $12.9M, up $3.9M (44%) YoY in Q3 2025 driven by PYRUKYND® volume increase
- • Net loss $103.4M vs net income $947.9M YoY in Q3 due to prior year Vorasidenib royalty sale gains
- • Best segment: PYRUKYND® product revenue $12.9M in Q3 2025; Worst: Overall net loss driven by increased R&D and SG&A expenses
- • Cash, cash equivalents, and marketable securities $1.3B at Sept 30, 2025; operating cash used $276.8M YTD
- • Outlook: Expect increased expenses for PYRUKYND® commercialization in thalassemia/SCD and pipeline advancement; no committed external funds except retained earn-out rights
Risk Factors
- • New regulatory risk: FDA extended PYRUKYND® sNDA PDUFA date to Dec 7, 2025 due to proposed REMS submission for hepatocellular injury risk
- • Material update clinical risk: USPI updated January 2025 adding liver injury safety info for PYRUKYND® at higher doses in thalassemia patients
- • Most impactful legal/compliance risk: Potential additional REMS requirements by FDA based on safety concerns could delay prescribing and restrict use
- • Operational risk near-term: Clinical trial enrollment delays due to limited patient pools in orphan diseases and geopolitical risks in Middle East sites
- • Financial risk concentration: Up to $130M development/regulatory milestones plus royalties owed under Alnylam license for siRNA candidate AG-236
Get deeper insights on AGIOS PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.